Use of nanoparticles to increase the systemic bioavailability of trans-resveratrol

Pharmaceutical Chemistry Journal

Volumn 44, Issue 2, 2010, Pages 74-76

  Oganesyan, E A ^a   Miroshnichenko, I I ^a   Vikhrieva, N S ^a   Lyashenko, A A ^a   Leshkov, S Yu ^a  

^a Joint Stock Company   (Russian Federation)

Author keywords

Bioavailability; Nanoparticles; Pharmacokinetics; Resveratrol

Indexed keywords

CHITOSAN; EUDRAGIT; NANOPARTICLE; PHOSPHATIDYLCHOLINE; RESVERATROL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; MOUSE; NONHUMAN; SINGLE DRUG DOSE;

EID: 77956455936     PISSN: 0091150X     EISSN: 15739031     Source Type: Journal    
DOI: 10.1007/s11094-010-0401-1     Document Type: Article

References (9)

1. T. Walle, F. Hsieh, M. H. DeLegge, et al., Drug Metab. Dispos., 32, 1377-1382 (2004).
2. C. Yu, Y. G. Shin, A. Chow, et al., Pharm. Res., 19, 1907-1914 (2002).
3. S. Sale, R. D. Verschoyle, D. Boocock, et al., Br. J. Cancer, 90, 736-744 (2004).
4. F. Sonvico, A. Cagnani, A. Rossi, et al., Int. J. Pharm., 324, 67-73 (2006).
5. S. Gibaud, A. N. Al Jabir, C. Ducki, et al., Int. J. Pharm., 269, 491-508 (2004).
6. P. V. Devarajan and G. S. Sonavane, Drug Dev. Ind. Pharm., 33, 101-111 (2007
7. N. Ubrich, C. Schmidt, R. Bodmeier, et al., Int. J. Pharm., 288, 169-175 (2005).
8. M. H. El-Shabouri, Int. J. Pharm., 249, 101-108 (2002).
9. D. J. Boocock, G. E. Faust, K. R. Patel, et al., Cancer Epidemiol. Biomarkers Prev, 16, 1246-1252 (2007).